China Universal Asset Management Co. Ltd. Makes New Investment in Inhibrx, Inc. (NASDAQ:INBX)

China Universal Asset Management Co. Ltd. acquired a new position in Inhibrx, Inc. (NASDAQ:INBX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,069 shares of the company’s stock, valued at approximately $47,000.

Separately, Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Inhibrx during the 4th quarter worth $348,000. Institutional investors own 82.46% of the company’s stock.

Inhibrx Stock Performance

INBX opened at $12.72 on Tuesday. The business has a 50-day moving average of $14.49 and a two-hundred day moving average of $14.64. Inhibrx, Inc. has a 12 month low of $10.80 and a 12 month high of $18.95.

Insider Buying and Selling at Inhibrx

In other news, Director Jon Faiz Kayyem bought 69,686 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was acquired at an average price of $14.23 per share, for a total transaction of $991,631.78. Following the acquisition, the director now owns 51,093 shares of the company’s stock, valued at $727,053.39. This trade represents a -374.80 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 22.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Separately, JMP Securities reissued a “market perform” rating on shares of Inhibrx in a research note on Wednesday, January 22nd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.